Evaluating efficacy and safety of differential therapy with atorvastatin, fenofibrate and their combination in patients with type 2 diabetes
Statins are the basis pharmacotherapy in the treatment of atherogenic dyslipidemia in diabetes mellitus (DM) type 2. [1, 3] For dyslipidemia with high triglyceride (TG) level and low concentrations of high density lipoprotein cholesterol (HDL-C) fibrates are traditionally used. [2, 4] Russia has limited experience with statins, fenofibrate and combination of these drugs in patients with diabetes type 2.